AUTISME-EUROPE AISBL

Their core work

Autisme-Europe is a Brussels-based European advocacy and network organization representing people with autism and their families across the continent. In H2020 projects, they serve as the critical bridge between clinical research and the autism community — providing real-world patient perspectives, facilitating access to affected populations, and ensuring research outcomes are relevant to people living with autism spectrum conditions. Their involvement spans clinical trials design (AIMS-2-TRIALS), neurodevelopmental comorbidity research (CANDY), and assistive technology development for autistic children (DE-ENIGMA).

What they specialise in

How they've shifted over time

In the earlier phase (2015–2017), Autisme-Europe participated in training and capacity-building networks (MiND, BRAINVIEW) focused on understanding the fundamentals of disrupted brain development and ADHD-autism overlap. From 2018 onward, their involvement shifted decisively toward translational medicine — clinical trials, biomarker identification, and investigating biological mechanisms like microbiome, inflammation, and genetic variants (AIMS-2-TRIALS, CANDY). This evolution reflects a move from broad neurodevelopmental training toward targeted, biomedically oriented autism research with direct clinical application.

Autisme-Europe is moving toward precision medicine in autism — expect growing involvement in biomarker-driven clinical trials and personalized intervention studies.

How they like to work

Autisme-Europe never coordinates projects but consistently joins large research consortia as a participant or third party — their value lies in representing the patient community, not in leading scientific work. With 95 unique partners across 18 countries, they maintain an exceptionally broad network for an advocacy organization. This makes them an ideal partner when a consortium needs authentic patient and family engagement, ethical oversight input, or dissemination channels reaching the European autism community.

With 95 consortium partners spanning 18 countries, Autisme-Europe has one of the broadest collaborative networks among autism-focused organizations in Europe. Their Brussels base and pan-European membership give them connections to clinical centers, universities, and patient organizations across the continent.

What sets them apart

Autisme-Europe occupies a rare niche: they are the primary pan-European voice of the autism community within H2020 research consortia. Unlike universities or hospitals that bring scientific capacity, AE brings legitimacy, community access, and the ability to translate research goals into language and priorities that matter to autistic people and their families. For any consortium needing genuine patient and public involvement (PPI) in autism or neurodevelopmental research, they are a near-irreplaceable partner.

Highlights from their portfolio

• AIMS-2-TRIALS
  Largest project by funding (EUR 267,470 to AE) and longest-running (2018–2026), representing Europe's flagship autism clinical trials initiative with the Innovative Medicines Initiative.
• CANDY
  Addresses the understudied intersection of autism, epilepsy, ADHD, and intellectual disability through biological mechanisms — microbiome, inflammation, and genetics.
• DE-ENIGMA
  Crosses from health into digital technology, developing human-robot interaction tools specifically designed for autistic children's social learning.